Adma Biologics Inc

Research Adma Biologics Inc (ADMA) on Bullrun: valuation model: 28.8% undervalued, market cap USD 1.94B, P/E 12.3. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerADMA
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Valuation signal28.8% undervalued
• Market capUSD 1.94B
• P/E12.3
• Financial periodFY2025
• RevenueUSD 510.17M
• Revenue growth19.6%
• Net incomeUSD 146.93M
• Free cash flowUSD 27.82M
• Gross margin57.4%

Valuation Snapshot

Bullrun's latest valuation model marks Adma Biologics Inc as 28.8% undervalued; latest market cap is USD 1.94B; P/E is 12.3.

About Adma Biologics Inc

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI;

Frequently asked questions

Is Adma Biologics Inc overvalued or undervalued?

Bullrun's valuation model currently marks Adma Biologics Inc as 28.8% undervalued.

What is Adma Biologics Inc's market cap?

Adma Biologics Inc's market capitalization is USD 1.94B.

What is Adma Biologics Inc's P/E ratio?

Adma Biologics Inc's price-to-earnings (P/E) ratio is 12.3.

What does Adma Biologics Inc do?

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.